 "GreenSignal Bio Pharma gets Sebi nod for IPO")
GreenSignal Bio Pharma (GSBPL) has received the Securities and Exchange Board of India's (Sebi) approval for its proposed initial public offering (IPO) through offer for sale.
The offering comprises 1,45,79,560 equity shares of GSBPL, representing 38 per cent of its equity share capital for cash through an offer for sale by the selling share-holders through the book building process, a company statement said in Mumbai.
GSBPL manufactures BCG vaccine against tuberculosis for newborn children. It is one of the four companies worldwide who have been WHO-prequalified to supply BCG vaccines to the UNICEF.
The company has established itself in the Indian vaccine market and its products are also exported to 17 countries either directly through the UNICEF or indirectly through other arrangements.
Indian Overseas Bank is the global co-ordinator and book running lead manager to the offer.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%